Facebook Linkedin RSS Twitter Youtube
Home 2023

Celgene

StockWatch: Antitrust Fears Dampen Support for $43B Pfizer-Seagen Deal
News

StockWatch: Antitrust Fears Dampen Support for $43B Pfizer-Seagen Deal

Celularity: Productizing Placental-Derived Stem Cells for Any Patient
Cancer

Celularity: Productizing Placental-Derived Stem Cells for Any Patient

You Can See Manhattan from Your Lab: $3B “Cove” Campus Announced in Jersey City
Drug Discovery

You Can See Manhattan from Your Lab: $3B “Cove” Campus Announced in Jersey City

Celgene, Acceleron Win FDA OK for Drug to Treat Anemia in Adults with Beta Thalassemia
Drug Discovery

Celgene, Acceleron Win FDA OK for Drug to Treat Anemia in Adults with Beta Thalassemia

Reliable Single Cell Outgrowth: Dark Art or Science?
Drug Discovery

Reliable Single Cell Outgrowth: Dark Art or Science?

Celgene, Immatics Launch Up-to-$1.5B+ Cancer T-Cell Collaboration
Cancer

Celgene, Immatics Launch Up-to-$1.5B+ Cancer T-Cell Collaboration

Merck & Co. Partners with Themis on Measles Virus Vector-Based Vaccines
Cancer

Merck & Co. Partners with Themis on Measles Virus Vector-Based Vaccines

Celgene Scraps $2.6B Deal, Licenses Jounce Antibody in Restructured Cancer Collaboration
Cancer

Celgene Scraps $2.6B Deal, Licenses Jounce Antibody in Restructured Cancer Collaboration

Top 10 M&A Deals of January–June 2019
A-Lists

Top 10 M&A Deals of January–June 2019

BMS Selling Celgene’s Otezla to Address FTC “Concerns” on $74B Deal
Drug Discovery

BMS Selling Celgene’s Otezla to Address FTC “Concerns” on $74B Deal

123...13Page 1 of 13
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.